Clinical Trial Search

Primary: Presence of a Cortical (C) Type of Cataractogenic Potential Events in Participants as Assessed and Agreed by 2 Independent, Treatment-masked Ophthalmologists Using the…

Primary: Number of Participants With a Mean Intact Parathyroid Hormone Value Between 150 and 300 pg/mL and a Calcium - Phosphorus Product Value < 55 mg^2/dL^2 — 30 Participants

Primary: Number of Participants Reporting Fever, Defined as Oral Temperature ≥ 101°F — 1; 1 participants

Primary: Central Macular Thickness (Difference in Mean Pre-post Changes by the Two Treatment Groups) — 2.78; 5.6 microns — p=0.7029

Primary: Bone Level Change on Radiographs — 2.91; 2.11; 1.70 mm

Primary: Change in Insulin Sensitivity Using FSIGT — 1.7; 2.4; 7.02 FSIGT units (x10^-4/min/uU/ml)

Primary: Percent Change in Pulmonary Artery Pressure Change From 1 Minute Pre-dose to 31 - 35 Minutes Post Dose — -1.9; -1.7 mm Hg

Primary: Patient Incidence of Biopsy-confirmed Acute Rejection (BCAR) at 6 Months — 6.2; 9.4; 1.9; 17.5 Percentage of Patients — p=0.4889

Primary: Change From Baseline (Log10 Cfu/cm²) in Count of Follicular P. Acnes — -1.94; -1.56 Log10 cfu/cm²

Primary: Seropositivity Rate (SPR) to Hepatitis A — 100; 100; 100; 100 Percentage of participants

Primary: Change From Baseline in Postprandial Glucose Excursion (PPGE) at the End of the Study (Week 4) — -1.775; -2.434 mmol/L

Primary: Change in Mean Headache Index Score Among Patients — -1.52 headache index score

Primary: Basal HDL-cholesterol Level — 39.5 mg/dL

Primary: Percentage of Subjects Achieving Canadian Low Density Lipoprotein Cholesterol (LDL-C) Target Goals (i.e. LDL-C ≤ 2.0 mmol/L) After 12 Weeks of Rosuvastatin Therapy — 87…

Primary: SNOT-16 Score (Sino-Nasal Outcomes Test) at Day 3 — 1.12; 1.14 Units on a scale — p=0.83